ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 ...

In Q1 2024, Abbott's FreeStyle Libre sales grew 25.5% to reach $1.5bn. The Plus version is gradually replacing the older ...

Abbott Laboratories ABT recently announced that the FreeStyle Libre 2 system's reimbursement coverage has been expanded by the French health authority to cover individuals using basal insulin as ...

Abbott initiated a nationwide voluntary medical device correction in February to emphasize instructions for the safe and proper use of its FreeStyle Libre®, FreeStyle Libre® 14 day, and ...

Abbott's world-leading 1 FreeStyle Libre 2 and 3 systems for people living with diabetes are now the only continuous glucose monitoring sensors 2 in the U.S. that users do not need to remove during ...

Abbott is taking steps to remind users of its FreeStyle Libre diabetes monitors to take good care of their batteries, after very rare reports of them swelling, overheating or catching fire.

Abbott's FreeStyle Libre 2 system has outstanding accuracy 1. No routine confirmatory finger pricks are required for treatment decisions, even when glucose is low, falling or rapidly changing.

Abbott initiated a voluntary medical device correction in February to emphasize instructions for its FreeStyle Libre®, FreeStyle Libre® 14 day and FreeStyle Libre® 2 Readers in the United ...

Abbott Laboratories received U.S. FDA clearance for the Freestyle Libre 2 and Freestyle Libre 3 continuous glucose monitoring (CGM) sensors for integration with automated insulin delivery (AID) ...

The added compatibility with Abbott’s FreeStyle Libre 2 Plus will open Insulet’s pump to more of the US diabetes market, estimated to be worth $9.6bn in 2023. By 2033, ...